Skip to main content

Thermo Fisher Scientific Value Stock - Dividend - Research Selection

Thermo fisher scientific

ISIN: US8835561023 , WKN: 857209

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide. Its Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of new drugs and vaccines, as well as diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets. Its Analytical Instruments segment offers instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and research and industrial markets, as well as clinical laboratories. Its Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; blood-test systems; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; products for cancer diagnosis and medical research in histology, cytology, and hematology; human leukocyte antigen typing and testing for organ transplant market; and healthcare market channel products. This segment serves healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. Its Laboratory Products and Services segment offers laboratory refrigerators and freezers, ultralow-temperature freezers and cryopreservation storage tanks, temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis and laboratory equipment; laboratory plastics; laboratory chemicals; research and safety market channel; and pharma services. The company was founded in 1956 and is headquartered in Waltham, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


How Investors May Respond To Thermo Fisher Scientific (TMO) Expanding Alzheimer’s Registry And Bioprocessing Tools

2025-12-19
Earlier this week, Thermo Fisher Scientific reported the first patient enrollment in its new international PPD CorEvitas Alzheimer’s Disease Registry and introduced next-generation Gibco Bacto CD Supreme media and feed to support higher-yield, chemically defined E. coli–based production of plasmid DNA and recombinant proteins. Together, these moves deepen Thermo Fisher’s role in real-world Alzheimer’s evidence generation while reinforcing its tools franchise in gene therapy and mRNA...

3 Mega-Cap Stocks with Warning Signs

2025-12-19
Megacap stocks dominate their sectors and their actions influence economies worldwide. The flip side though is that their sheer size means they have less room for explosive growth as scale works against them.

Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer’s Disease Registry to Advance Real-World Evidence in Neurodegenerative Care

2025-12-18
WALTHAM, Mass., December 18, 2025--Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer’s Disease Registry to Advance Real-World Evidence in Neurodegenerative Care.

North America Poised for Highest Growth in Microplastic Analysis Market with 8.5% CAGR

2025-12-17
The global microplastic analysis market is set to grow from USD 266.9 million in 2025 to USD 383.1 million by 2030 at a CAGR of 7.5%. Growth is driven by increased research funding, rising proteomics research, and heightened awareness of microplastic pollution risks. The instruments segment will dominate the market in 2025, with substantial demand for reagents and consumables fueled by regulatory pressures. The water testing segment is experiencing rapid growth due to stricter water quality regu

TMO Stock Set to Gain From the Expansion of Gibco Bacto Portfolio

2025-12-16
Thermo Fisher expands its Gibco Bacto CD portfolio with new formulations aimed at boosting E. coli-based plasmid DNA and protein production efficiency.

OlivePoint Capital Acquires 3900 Paramount Parkway in Raleigh–Durham, Expanding Its High-Conviction Office Special Situations Strategy

2025-12-15
LOS ANGELES, December 15, 2025--OlivePoint acquires a Class A Raleigh office 100% leased to PPD/Thermo Fisher, highlighting its strategy to target mispriced, credit-backed assets.

Thermo Fisher Scientific Expands Gibco™ Bacto™ Portfolio with Next-Generation, Chemically Defined Media to Boost E. coli Biomanufacturing Productivity

2025-12-15
WALTHAM, Mass., December 15, 2025--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of Gibco™ Bacto™ CD Supreme FPM Plus and Gibco™ Bacto™ CD Supreme Feed (2X), two next-generation chemically-defined formulations that expand the Gibco™ Bacto™ CD portfolio to enhance and simplify plasmid DNA and recombinant protein production using Escherichia coli (E. coli).

3 Profitable Stocks Walking a Fine Line

2025-12-15
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Taking Stock of Thermo Fisher Scientific (TMO) Valuation After Analyst Upgrades and Bioprocessing, Cardio Testing Moves

2025-12-14
Thermo Fisher Scientific (TMO) just picked up fresh buy ratings on the back of its Asian bioprocessing expansion and a new cardiovascular risk testing partnership, and investors are treating that combination as a meaningful confidence signal. See our latest analysis for Thermo Fisher Scientific. Although Thermo Fisher’s share price is slightly softer in the very short term, a roughly 21 percent 90 day share price return suggests momentum is rebuilding as investors reprice its Asia buildout...

Becton Dickinson, Bio-Rad, and Thermo Fisher Propel Safety and Automation in Blood Collection Tubes—New Market Report Highlights $7Billion Opportunity

2025-12-12
The blood collection tubes market presents opportunities through innovation in automated systems, advanced materials, and digital traceability to enhance workflow efficiency and compliance. Demand is driven by personalized medicine, diagnostic volume growth, and regulatory needs, with a focus on agility and regional adaptation. Blood Collection Tubes Market Blood Collection Tubes Market Dublin, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The "Blood Collection Tubes Market - Global Forecast 2025-2032" has